Thursday's Trending Stocks
The short-sale attack on Tempus AI (TEM) heated up on Wednesday. The stock’s rally halted after it lost 19.23% to close at $53.20. Short sellers hold an 11.29% short interest.Spruce Point Capital published a short report against Tempus. The firm previously posted a short report against Him & Hers (HIMS). HIMS stock went on to rise from the $20 - $30 range to over $60 in early May.Salesforce (CRM) will trade in a steady range after posting first-quarter revenue of $9.83 billion (+7.7% Y/Y). Non-GAAP EPS was $2.58. The company raised its full-year 2026 revenue guidance, too. It expects revenue to grow by 8.5%, with a profit margin of 17%. CRM stock is attractive at current prices.Box (BOX) may pull back after gaining over 17% on Tuesday. The company reported a 4.4% Y/Y revenue growth, to $276.27 million in the first quarter.In the retail sector, Victoria’s Secret (VSCO) might continue its downward trend. Activists increased their holdings to 13%. They want to shake up the company. However, the company adopted a poison pill. This is unfortunate since it prevents activists from pressuring change in the company.In the entertainment and communications market, watch Warner Bros Discovery (WBD). The stock traded above $10.00. During the Memorial Day weekend, Disney (DIS), Paramount (PARA), and Marcus (MCS) benefited from strong ticket movie revenue. WBD’s stock benefited from the success of Final Destination: Bloodlines.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


